恩替卡韦对乙型肝炎患者干扰素诱导单核因子作用  

The function of entecavir to Mig in patients with chronic hepatitis

作　　者：张利霞[1] 

机构地区：[1]遵义医学院第五附属(珠海)医院感染科,广东珠海519100

出　　处：《国际检验医学杂志》2016年第19期2661-2662,2666,共3页International Journal of Laboratory Medicine

基　　金：广东省珠海市卫生和计划生育委员会医学科研课题(2014087)

摘　　要：目的探讨恩替卡韦抗病毒治疗过程中不同时期慢性乙型肝炎(HBV)患者外周血中干扰素诱导单核因子(Mig)的水平变化。方法 40例应用恩替卡韦治疗的慢性乙型肝炎患者,采用ELISA法定量检测治疗前后的血清Mig水平,并同时检测乙型肝炎表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)、HBV DNA水平。结果使用恩替卡韦抗病毒治疗后,血清Mig及HBsAg、HBeAg、HBV DNA明显下降,且治疗后24周比治疗后12周下降明显,差异均有统计学意义(P<0.05)。结论恩替卡韦能下调Mig,降低血清HBsAg、HBeAg、HBV DNA水平,有利于控制疾病进展。Objective To investigate the function of entecavir toγ-interferon induced monokine（Mig）for chronic hepatitis B patients.Methods The 40 cases of chronic hepatitis B patients were treated with entecavir tablet.The Mig level were detected by ELISA in 40 patients in the time before and after treatment of 12 weeks and 24weeks;HBsAg,HBeAg level were analyzed by using electrochemiluminescence and HBV-DNA was tested by using real-time quantitative PCR（FQ-PCR）.Results Mig and HBsAg,HBeAg,HBV DNA levels were significantly lower than before treatment in the 40patients（P〈0.05）.Compared with those in the time of 12 weeks after treatment,those indexes after treatment 24 weeks were significantly decreased（P〈0.05）.Conclusion Entecavir treatment can reduce the level of Mig,HBsAg and HBeAg,HBV DNA,and help to control disease progression in chronic hepatitis B.

关 键 词：慢性乙型肝炎 干扰素诱导单核因子 恩替卡韦 

分 类 号：R512.62[医药卫生—内科学]